{
    "title": "114_hr639",
    "content": "The Act titled \"Improving Regulatory Transparency for New Medical Therapies Act\" amends the Federal Food, Drug, and Cosmetic Act regarding the scheduling of substances in new FDA-approved drugs. Approval of a drug under the Controlled Substances Act will not take effect until the interim final rule controlling the drug is issued. The term \"date of approval\" refers to the later of the date of application submission. The Act \"Improving Regulatory Transparency for New Medical Therapies Act\" amends the Federal Food, Drug, and Cosmetic Act regarding substance scheduling in new FDA-approved drugs. Approval under the Controlled Substances Act is contingent on the issuance of an interim final rule. The term \"date of approval\" is defined as the later of the application approval date or the issuance of the interim final rule. Under the Controlled Substances Act, approval of an application is dependent on the issuance of an interim final rule. The \"date of approval\" refers to the later of the application approval date or the interim final rule issuance date. Additionally, the effective date of approval for animal drugs is addressed in the Federal Food, Drug, and Cosmetic Act. The approval of an application under the Controlled Substances Act is tied to the issuance of an interim final rule. The \"date of approval\" is defined as the later of the application approval date or the interim final rule issuance date. Additionally, conditional approval for applications is addressed in the Federal Food, Drug, and Cosmetic Act. Conditional approval under the Federal Food, Drug, and Cosmetic Act is contingent upon the issuance of an interim final rule controlling the drug under the Controlled Substances Act. The \"date of approval\" is determined as the later of the conditional approval date or the interim final rule issuance date. Conditional approval under the Federal Food, Drug, and Cosmetic Act is dependent on the issuance of an interim final rule controlling the drug under the Controlled Substances Act. The approval date is determined as the later of the conditional approval date or the interim final rule issuance date. In accordance with the Controlled Substances Act, newly approved drugs must be scheduled by the Attorney General within 90 days of recommendation by the Secretary of Health and Human Services. The Attorney General must issue an interim final rule to control a drug recommended for scheduling within 90 days of receiving the recommendation from the Secretary of Health and Human Services. The recommendation must be based on scientific and medical evaluation or approval of an application under specific acts. The Attorney General must issue an interim final rule for a drug recommended for scheduling within 90 days of receiving the recommendation from the Secretary of Health and Human Services. The rule becomes effective immediately without needing to show cause, allowing for public comment and hearings before a final rule is issued. Additionally, there are amendments to Section 156 of title 35, United States Code, regarding the extension of patent terms for drug products. In subsection (d)(1), a drug product must be marketed or used within sixty days of the covered date. If the Secretary of Health and Human Services notifies the sponsor of a drug product for controlled substances, it is considered approved for commercial marketing. The term \"covered date\" refers to the date of application approval under relevant provisions of the Public Health Service Act or Federal Food, Drug, and Cosmetic Act. In subsection (d)(1), a drug product must be marketed or used within sixty days of the covered date, which is the date of application approval under relevant provisions of the Public Health Service Act or Federal Food, Drug, and Cosmetic Act. Additionally, for registration to manufacture a controlled substance for clinical trial use, the Attorney General must act within 180 days of application acceptance. The Attorney General must register an applicant within 180 days of application acceptance for manufacturing a controlled substance for clinical trial use. Additionally, re-exportation among members of the European Economic Area is addressed in Section 1003 of the Controlled Substances Import and Export Act. Section 1003 of the Controlled Substances Import and Export Act is amended to allow re-exportation among members of the European Economic Area, with specific conditions to be met by each subsequent country involved. The Controlled Substances Import and Export Act is amended to allow re-exportation among members of the European Economic Area, with specific conditions to be met by each subsequent country involved. This includes documentation certification and information provision within 30 days of re-exportation. The Controlled Substances Import and Export Act is amended to allow re-exportation among European Economic Area countries without impediments. The Attorney General must receive documentation certifying re-exportation and information about the consignee, country, and product. No regulations can hinder the re-exportation process, including time constraints or information requirements prior to exportation. The curr_chunk is about the roles of the Speaker of the House of Representatives and the Vice President of the United States as President of the Senate."
}